AGEN – Agenus Inc.

Agenus Inc.

AGEN

$7.20

Name : Agenus Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $325,548,672.00

EPSttm : 0.23

Agenus Inc.

$7.20

2.49%

$0.175

AGEN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.51

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

0.02

EPS Last/This Y

0.5

EPS This/Next Y

-0.61

Price

7.01

Target Price

Analyst Recom

Performance Q

1.74

Upside

35.2%

Beta

1.52

Ticker: AGEN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	AGEN	7.43	0.28	0.12	18309
2026-10-13	AGEN	6.95	0.28	1.84	18308
2026-10-14	AGEN	6.47	0.29	0.09	18362
2026-10-15	AGEN	6.68	0.28	0.01	18398
2026-10-16	AGEN	6.04	0.28	0.53	18422
2026-10-19	AGEN	6.17	0.29	1.25	16957
2026-10-20	AGEN	6.44	0.29	0.06	17130
2026-10-21	AGEN	6.4	0.29	0.02	17220
2026-10-22	AGEN	6.51	0.29	0.00	17270
2026-10-23	AGEN	6.32	0.29	0.75	17233
2026-10-26	AGEN	6.15	0.29	5.00	17257
2026-10-27	AGEN	6.66	0.30	1.14	17332
2026-10-28	AGEN	7.14	0.30	1.12	17473
2026-10-29	AGEN	7.09	0.30	3.00	17575
2026-10-30	AGEN	6.83	0.29	0.31	17563
2026-11-02	AGEN	6.45	0.29	19.25	17569
2026-11-03	AGEN	6.68	0.30	0.00	17613
2026-11-04	AGEN	6.98	0.30	0.90	17685
2026-11-05	AGEN	6.43	0.30	1.72	17726
2026-11-06	AGEN	7.14	0.30	0.58	17735
2026-11-09	AGEN	7.16	0.30	1.63	17821
2026-11-10	AGEN	7.02	0.30	5.34	17874
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	AGEN	7.43	103.4	-138.6	0.50
2026-10-13	AGEN	6.93	103.4	-139.1	0.50
2026-10-14	AGEN	6.47	103.4	-139.1	0.50
2026-10-15	AGEN	6.68	103.4	-138.7	0.50
2026-10-16	AGEN	6.03	103.4	-139.5	0.50
2026-10-19	AGEN	6.17	103.4	-138.0	0.50
2026-10-20	AGEN	6.17	103.4	-138.0	0.50
2026-10-21	AGEN	6.42	103.4	-137.8	0.50
2026-10-22	AGEN	6.52	103.4	-138.0	0.50
2026-10-23	AGEN	6.32	103.4	-138.0	0.50
2026-10-26	AGEN	6.16	103.4	-138.6	0.50
2026-10-27	AGEN	6.66	103.4	-137.3	0.50
2026-10-28	AGEN	7.14	103.4	-137.4	0.50
2026-10-29	AGEN	7.09	103.4	-138.3	0.50
2026-10-30	AGEN	6.84	103.4	-138.7	0.50
2026-11-02	AGEN	6.52	103.4	-138.8	0.50
2026-11-03	AGEN	6.67	103.4	-138.6	0.50
2026-11-04	AGEN	7.00	103.4	-137.6	0.50
2026-11-05	AGEN	6.43	103.4	-139.2	0.50
2026-11-06	AGEN	7.14	103.4	-136.9	0.50
2026-11-09	AGEN	7.16	103.4	-78.4	0.50
2026-11-10	AGEN	7.01	103.4	-78.7	0.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	AGEN	0.00	17.86	17.09
2026-10-13	AGEN	0.00	17.86	17.09
2026-10-14	AGEN	0.00	17.86	17.09
2026-10-15	AGEN	0.00	17.86	17.09
2026-10-16	AGEN	0.00	17.86	17.09
2026-10-19	AGEN	0.00	17.88	17.08
2026-10-20	AGEN	0.00	17.88	17.08
2026-10-21	AGEN	0.00	17.88	17.08
2026-10-22	AGEN	0.00	17.88	17.08
2026-10-23	AGEN	0.00	17.88	17.08
2026-10-26	AGEN	0.00	17.56	17.08
2026-10-27	AGEN	0.00	17.56	17.54
2026-10-28	AGEN	0.00	17.56	17.54
2026-10-29	AGEN	0.00	17.56	17.54
2026-10-30	AGEN	0.00	17.56	17.54
2026-11-02	AGEN	0.00	17.50	17.54
2026-11-03	AGEN	0.00	17.50	17.54
2026-11-05	AGEN	0.00	17.50	17.54
2026-11-06	AGEN	0.00	17.50	17.54
2026-11-09	AGEN	0.00	11.24	17.51
2026-11-10	AGEN	0.00	11.24	17.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.02

Avg. EPS Est. Current Quarter

0.04

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

Institutional Transactions

11.24

Beta

1.52

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

92.2

Max Drawdown 5-Year %

-98.3

Target Price

P/E

9.67

Forward P/E

PEG

P/S

2.37

P/B

P/Free Cash Flow

EPS

0.73

Average EPS Est. Cur. Y

0.5

EPS Next Y. (Est.)

-0.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.99

Relative Volume

0.69

Return on Equity vs Sector %

-45.5

Return on Equity vs Industry %

-25.8

EPS 1 7Days Diff

-1.5

EPS 1 30Days Diff

-1.46

EBIT Estimation

-78.7

◆ AGEN Healthcare

$7.02

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

17/25

Volume

9/15

Valuation

10/20

TP/AR

4/10

Options

7/10

RSI

50.2

Range 1M

54.2%

Sup Dist

0.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

14/30

Estimates

6/20

Inst/Vol

7/15

Options

5/10

EPS Yr

114%

EPS NY

-332.1%

52W%

55.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +256.1% upside

Quality

13/30

Valuation

16/30

Growth

8/25

Stability

5/10

LT Trend

0/5

Upside

+256.1%

Quality

AGEN — P/E HistoricalBiotechnology

Agenus Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 81

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN

Latest News

—

Caricamento notizie per AGEN…

stock quote shares AGEN – Agenus Inc. Stock Price stock today

news today AGEN – Agenus Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AGEN – Agenus Inc. yahoo finance google finance

stock history AGEN – Agenus Inc. invest stock market

stock prices AGEN premarket after hours

ticker AGEN fair value insiders trading

AGEN – Agenus Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: AGEN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y